**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

In a retrospective chart review of 50 patients conducted from August 2016 to February 2018, seven patients \[*ages and sexes not stated*\] were described, who developed cytomegalovirus (CMV) colitis (1 patient), asymptomatic BK viruria (1 patient), CMV reactivation (1 patient), pulmonary parainfluenza virus infection (1 patient), pulmonary coronavirus infection (1 patient), oral cavity coxsackie virus infection (1 patient) and fungal pneumonia (1 patient) during treatment with fludarabine, busulfan and antithymocyte globulin \[thymoglobulin\] as conditioning regimen, and cyclophosphamide, mesna and ciclosporin \[cyclosporine\] for prophylaxis against graft versus host disease (GVHD) and graft rejection \[*not all routes, dosages and outcomes stated; durations of treatments to reaction onsets not stated*\].

All patients were diagnosed with haematological malignancies and scheduled for haploidentical allogeneic haematopoietic stem cell transplantation (haploHSCT). All patients received conditioning regimen comprising IV fludarabine 30 mg/m^2^ daily on days -5 to -2, busulfan 3.2 mg/m^2^ daily on days -3 and -2, antithymocyte globulin 0.5 mg/kg on day -3 and 2 mg/kg on day -2 and day -1 followed by total body irradiation on day -1. On first day of conditioning, all patients were started on ursodeoxycholic acid for prophylaxis against sinusoidal obstruction syndrome. Subsequently, all patients were infused with peripheral blood stem cells graft on day 0 and received post-transplant immunosuppressants for prophylaxis against GVHD and graft rejection. Post-transplant immunosuppressants included IV cyclophosphamide 50 mg/kg daily on days 3 and 4, four doses of mesna on days 3 and 4 at a daily dose of 80% of cyclophosphamide dose and IV ciclosporin 2.5 mg/kg every 12 hours on day 5. The dose of ciclosporin was adjusted to achieve a therapeutic concentration of 200 to 400 µg/L. All patients were started on filgrastim on day 7 to increase neutrophil count and prophylactic antimicrobial therapy with posaconazole, aciclovir ciprofloxacin and pentamidine. Thereafter, the patients developed CMV colitis (1 patient), asymptomatic BK viruria (1 patient), CMV reactivation (1 patient), pulmonary parainfluenza virus infection (1 patient), pulmonary coronavirus infection (1 patient), oral cavity coxsackie virus infection (1 patient) and fungal pneumonia leading to death due to its complications (1 patient).

**Author comment:** *\"However, the use of \[antithymocyte globulin\] is also associated with delayed immune reconstitution and increased infective complications, particularly viral reactivations with CMV or EBV. Due to the higher degree of immunosuppression, haploHSCT recipients have an increased risk of infectious complications, particularly viral infections including CMV reactivation. High incidence of CMV reactivation was noted in our study\".*
